Skip Navigation

Annals of Oncology 2008 19(10):1663; doi:10.1093/annonc/mdn660
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Prognosis and therapy of breast carcinomas according to HER2 score
 
The standardization of the HER2 score and recent changes in therapeutic modalities in both the surgical and pharmaceutical adjuvant arenas suggest the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinomas. Such analyses are possible even with a relatively short follow-up period since the prognostic impact of HER2 positivity is related to the first 3–4 years after surgery. In . . . [Full Text of this Article]


   Testing standard vs. daily radiosensitisation by cisplatin for limited small-cell lung cancer
 

   XELOX vs. FOLFOX-4 as second-line therapy in metastatic colorectal cancer
 

   Pulmonary function in Hodgkin's lymphoma patients
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?